Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction
0
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: Angiotensin II type 1 receptor blockers (ARBs) have not been adequately evaluated in patients without left ventricular (LV) dysfunction or heart failure after acute myocardial infarction (AMI). Methods: Between November 2005 and January 2008, 6,781 patients who were not receiving angiotensin-converting enzyme inhibitors (ACEIs) or ARBs were selected from the Korean AMI Registry. The primary endpoints were 12-month major adverse cardiac events (MACEs) including death and recurrent AMI. Results: Seventy percent of the patients were Killip class 1 and had a LV ejection fraction ≥ 40%. The prescription rate of ARBs was 12.2%. For each patient, a propensity score, indicating the likelihood of using ARBs during hospitalization or at discharge, was calculated using a non-parsimonious multivariable logistic regression model, and was used to match the patients 1:4, yielding 715 ARB users versus 2,860 ACEI users. The effect of ARBs on in-hospital mortality and 12-month MACE occurrence was assessed using matched logistic and Cox regression models. Compared with ACEIs, ARBs significantly reduced in-hospital mortality (1.3% vs. 3.3%; hazard ratio [HR], 0.379; 95% confidence interval [CI], 0.190 to 0.756; p = 0.006) and 12-month MACE occurrence (4.6% vs. 6.9%; HR, 0.661; 95% CI, 0.457 to 0.956; p = 0.028). However, the benefit of ARBs on 12-month mortality compared with ACEIs was marginal (4.3% vs. 6.2%; HR, 0.684; 95% CI, 0.467 to 1.002; p = 0.051). Conclusions: Our results suggest that ARBs are not inferior to, and may actually be better than ACEIs in Korean patients with AMI.
Abstract
Background/Aims: Angiotensin II type 1 receptor blockers (ARBs) have not been adequately evaluated in patients without left ventricular (LV) dysfunction or heart failure after acute myocardial infarction (AMI). Methods: Between November 2005 and January 2008, 6,781 patients who were not receiving angiotensin-converting enzyme inhibitors (ACEIs) or ARBs were selected from the Korean AMI Registry. The primary endpoints were 12-month major adverse cardiac events (MACEs) including death and recurrent AMI. Results: Seventy percent of the patients were Killip class 1 and had a LV ejection fraction ≥ 40%. The prescription rate of ARBs was 12.2%. For each patient, a propensity score, indicating the likelihood of using ARBs during hospitalization or at discharge, was calculated using a non-parsimonious multivariable logistic regression model, and was used to match the patients 1:4, yielding 715 ARB users versus 2,860 ACEI users. The effect of ARBs on in-hospital mortality and 12-month MACE occurrence was assessed using matched logistic and Cox regression models. Compared with ACEIs, ARBs significantly reduced in-hospital mortality (1.3% vs. 3.3%; hazard ratio [HR], 0.379; 95% confidence interval [CI], 0.190 to 0.756; p = 0.006) and 12-month MACE occurrence (4.6% vs. 6.9%; HR, 0.661; 95% CI, 0.457 to 0.956; p = 0.028). However, the benefit of ARBs on 12-month mortality compared with ACEIs was marginal (4.3% vs. 6.2%; HR, 0.684; 95% CI, 0.467 to 1.002; p = 0.051). Conclusions: Our results suggest that ARBs are not inferior to, and may actually be better than ACEIs in Korean patients with AMI.
참고문헌 (19)
- The CONSENSUS Trial Study Group, "Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)", N Engl J Med, 316, pp.1429~1435 (1987)
- The Acute Infarction Ramipril Efficacy(AIRE)Study Investigators, "Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure", Lancet, 342, pp.821~828 (1993)
- Pfeffer MA, "Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators", N Engl J Med, 327, pp.669~677 (1992)
- ISIS-4 (Fourth International Study of Infarct Survival)Collaborative Group, "ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction", Lancet, 345, pp.669~685 (1995)
- Van de Werf F, "Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology", Eur Heart J, 29, pp.2909~2945 (2008)
- Task Force for Diagnosis and Treatment of Non-STSegment Elevation Acute Coronary Syndromes of European Society of Cardiology, "Guidelines for the diagnosis and treatment of non-STsegment elevation acute coronary syndromes", Eur Heart J, 28, pp.1598~1660 (2007)
- Levy BI, "Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system", Circulation, 109, pp.8~13 (2004)
- Dickstein K, "Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan", Lancet, 360, pp.752~760 (2002)
- Pfeffer MA, "Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both", N Engl J Med, 349, pp.1893~1906 (2003)
- McMurray J, "The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)", J Am Coll Cardiol, 47, pp.726~733 (2006)
- Lee JH, "Predictors of six-month major adverse cardiac events in 30-day survivors after acute myocardial infarction (from the Korea Acute Myocardial Infarction Registry)", Am J Cardiol, 104, pp.182~189 (2009)
- "Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology", American College of Cardiology Committee for the redefinition of myocardial infarction, 2000, pp.21, 1502~1513
- Rosenbaum PR, "The central role of the propensity score in observational studies for causal effects", Biometrika, 70, pp.41~55 (1983)
- Bhatt DL, "International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis", JAMA, 295, pp.180~189 (2006)
- Hansen ML, "Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction", Br J Clin Pharmacol, 65, pp.217~223 (2008)
- ACE Inhibitor Myocardial Infarction Collaborative Group, "Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials", Circulation, 97, pp.2202~2212 (1998)
- Kohro T, "Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD)study", Circ J, 71, pp.1835~1840 (2007)
- Morimoto T, "An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors", J Eval Clin Pract, 10, pp.499~509 (2004)
- Woo KS, "Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities)", Am J Cardiol, 75, pp.967~968 (1995)